Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score

被引:60
作者
Huang, Eugene H.
Strom, Eric A.
Perkins, George H.
Oh, Julia L.
Chen, Allen M.
Meric-Bernstam, Funda
Hunt, Kelly K.
Sahin, Aysegul A.
Hortobagyi, Gabriel N.
Buchholz, Thomas A.
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2006年 / 66卷 / 02期
关键词
breast conservation; prognostic index; mastectomy;
D O I
10.1016/j.ijrobp.2006.04.046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: We previously developed a prognostic index that stratified patients treated with breast conservation therapy (BCT) after neoadjuvant chemotherapy into groups with different risks for local-regional recurrence (LRR). The purpose of this study was to compare the rates of LRR as a function of prognostic index score for patients treated with BCT or mastectomy plus radiation after neoadjuvant chemotherapy. Methods: We retrospectively analyzed 815 patients treated with neoadjuvant chemotherapy, surgery, and radiation. Patients were assigned an index score from 0 to 4 and given I point for the presence of each factor: clinical N2 to N3 disease, lymphovascular invasion, pathologic size > 2 cm, and multifocal residual disease. Results: The 10-year LRR rates were very low and similar between the mastectomy and BCT groups for patients with an index score of 0 or 1. For patients with a score of 2, LRR trended lower for those treated with mastectomy vs. BCT (12% vs. 28%, p = 0.28). For patients with a score of 3 to 4, LRR was significantly lower for those treated with mastectomy vs. BCT (19% vs. 61%, p = 0.009). Conclusion: This analysis suggests that BCT can provide excellent local-regional treatment for the vast majority of patients after neoadjuvant chemotherapy. For the few patients with a score of 3 to 4, LRR was > 60% after BCT and was < 20% with mastectomy. If these findings are confirmed in larger randomized studies, the prognostic index may be useful in helping to select the type of surgical treatment for patients treated with neoadjuvant chemotherapy, surgery, and radiation. (c) 2006 Elsevier Inc.
引用
收藏
页码:352 / 357
页数:6
相关论文
共 17 条
[1]   Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute [J].
Bonadonna, G ;
Valagussa, P ;
Brambilla, C ;
Ferrari, L ;
Moliterni, A ;
Terenziani, M ;
Zambetti, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :93-100
[2]   Neoadjuvant chemotherapy for breast carcinoma - Multidisciplinary considerations of benefits and risks [J].
Buchholz, TA ;
Hunt, KK ;
Whitman, GJ ;
Sahin, AA ;
Hortobagyi, GN .
CANCER, 2003, 98 (06) :1150-1160
[3]   Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer [J].
Buzdar, AU ;
Singletary, SE ;
Theriault, RL ;
Booser, DJ ;
Valero, V ;
Ibrahim, N ;
Smith, TL ;
Asmar, L ;
Frye, D ;
Manuel, N ;
Kau, SW ;
McNeese, M ;
Strom, E ;
Hunt, K ;
Ames, F ;
Hortobagyi, GN .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3412-3417
[4]   Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma - Effective clinical downstaging allows breast preservation and predicts outstanding local control and survival [J].
Cance, WG ;
Carey, LA ;
Calvo, BF ;
Sartor, C ;
Sawyer, L ;
Moore, DT ;
Rosenman, J ;
Ollila, DW ;
Graham, M .
ANNALS OF SURGERY, 2002, 236 (03) :295-303
[5]   Breast conservation after neoadjuvant chemotherapy: The M.D. Anderson Cancer Center experience [J].
Chen, AM ;
Meric-Bernstam, F ;
Hunt, KK ;
Thames, HD ;
Oswald, MJ ;
Outlaw, ED ;
Strom, EA ;
McNeese, MD ;
Kuerer, HM ;
Ross, MI ;
Singletary, SE ;
Ames, FC ;
Feig, BW ;
Sahin, AA ;
Perkins, GH ;
Schechter, NR ;
Hortobagyi, GN ;
Buchholz, TA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2303-2312
[6]   Breast conservation after neoadjuvant chemotherapy - A prognostic index for clinical decision-making [J].
Chen, AM ;
Meric-Bernstam, F ;
Hunt, KK ;
Thames, HD ;
Outlaw, ED ;
Strom, EA ;
McNeese, MD ;
Kuerer, HM ;
Ross, MI ;
Singletary, SE ;
Ames, FC ;
Feig, BW ;
Sahin, AA ;
Perkins, GH ;
Babiera, G ;
Hortobagyi, GN ;
Buchholz, TA .
CANCER, 2005, 103 (04) :689-695
[7]   Effect of preoperative chemotherapy on the outcome of women with operable breast cancer [J].
Fisher, B ;
Bryant, J ;
Wolmark, N ;
Mamounas, E ;
Brown, A ;
Fisher, ER ;
Wickerham, DL ;
Begovic, M ;
DeCillis, A ;
Robidoux, A ;
Margolese, RG ;
Cruz, AB ;
Hoehn, JL ;
Lees, AW ;
Dimitrov, NV ;
Bear, HD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2672-2685
[8]  
HARRIS E, 1991, SURVIVORSHIP ANAL CL
[9]   Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy [J].
Huang, EH ;
Tucker, SL ;
Strom, EA ;
McNeese, MD ;
Kuerer, HM ;
Hortobagyi, GN ;
Buzdar, AU ;
Valero, V ;
Perkins, GH ;
Schechter, NR ;
Hunt, KK ;
Sahin, AA ;
Buchholz, TA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (02) :351-357
[10]   Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy [J].
Huang, EH ;
Tucker, SL ;
Strom, EA ;
McNeese, MD ;
Kuerer, HM ;
Buzdar, AU ;
Valero, V ;
Perkins, GH ;
Schechter, NR ;
Hunt, KK ;
Sahin, AA ;
Hortobagyi, GN ;
Buchholz, TA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (23) :4691-4699